%0 Journal Article %1 Cherubini2011 %A Cherubini, Antonio %A Oristrell, Joaquim %A Pla, Xavier %A Ruggiero, Carmelinda %A Ferretti, Roberta %A Diestre, Germán %A Clarfield, A Mark %A Crome, Peter %A Hertogh, Cees %A Lesauskaite, Vita %A Prada, Gabriel-Ioan %A Szczerbinska, Katarzyna %A Topinkova, Eva %A Sinclair-Cohen, Judith %A Edbrooke, David %A Mills, Gary H %D 2011 %J Archives of internal medicine %K 80andover Aged ClinicalTrialsasTopic Databases Factual HeartFailure HeartFailure:drugtherapy Humans LogisticModels PatientSelection %N 6 %P 550-6 %R 10.1001/archinternmed.2011.31 %T The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. %U http://archinte.ama-assn.org/cgi/content/abstract/171/6/550 http://www.ncbi.nlm.nih.gov/pubmed/21444844 %V 171 %X BACKGROUND: Much clinical research of relevance to elderly patients examines individuals who are younger than those who have the disease in question. A good example is heart failure. Therefore, we investigated the extent of exclusion of older individuals in ongoing clinical trials regarding heart failure. METHODS: In the context of the Increasing the PaRticipation of the ElDerly in Clinical Trials (PREDICT) study, data from ongoing clinical trials regarding heart failure were extracted from the World Health Organization Clinical Trials Registry Platform on December 1, 2008. Main outcome measures were the proportion of trials excluding patients by an arbitrary upper age limit or by other exclusion criteria that might indirectly cause limited recruitment of older individuals. We classified exclusion criteria into 2 categories: justified or poorly justified. RESULTS: Among 251 trials investigating treatments for heart failure, 64 (25.5%) excluded patients by an arbitrary upper age limit. Such exclusion was significantly more common in trials conducted in the European Union than in the United States (31/96 32.3% vs 17/105 16.2%; P = .007) and in drug trials sponsored by public institutions vs those by private entities (21/59 35.6% vs 5/36 13.9%; P = .02). Overall, 109 trials (43.4%) on heart failure had 1 or more poorly justified exclusion criteria that could limit the inclusion of older individuals. A similar proportion of clinical trials with poorly justified exclusion criteria was found in pharmacologic and nonpharmacologic trials. CONCLUSION: Despite the recommendations of national and international regulatory agencies, exclusion of older individuals from ongoing trials regarding heart failure continues to be widespread.

@article{Cherubini2011, abstract = {BACKGROUND: Much clinical research of relevance to elderly patients examines individuals who are younger than those who have the disease in question. A good example is heart failure. Therefore, we investigated the extent of exclusion of older individuals in ongoing clinical trials regarding heart failure. METHODS: In the context of the Increasing the PaRticipation of the ElDerly in Clinical Trials (PREDICT) study, data from ongoing clinical trials regarding heart failure were extracted from the World Health Organization Clinical Trials Registry Platform on December 1, 2008. Main outcome measures were the proportion of trials excluding patients by an arbitrary upper age limit or by other exclusion criteria that might indirectly cause limited recruitment of older individuals. We classified exclusion criteria into 2 categories: justified or poorly justified. RESULTS: Among 251 trials investigating treatments for heart failure, 64 (25.5%) excluded patients by an arbitrary upper age limit. Such exclusion was significantly more common in trials conducted in the European Union than in the United States (31/96 [32.3%] vs 17/105 [16.2%]; P = .007) and in drug trials sponsored by public institutions vs those by private entities (21/59 [35.6%] vs 5/36 [13.9%]; P = .02). Overall, 109 trials (43.4%) on heart failure had 1 or more poorly justified exclusion criteria that could limit the inclusion of older individuals. A similar proportion of clinical trials with poorly justified exclusion criteria was found in pharmacologic and nonpharmacologic trials. CONCLUSION: Despite the recommendations of national and international regulatory agencies, exclusion of older individuals from ongoing trials regarding heart failure continues to be widespread.}, added-at = {2023-02-03T11:44:35.000+0100}, author = {Cherubini, Antonio and Oristrell, Joaquim and Pla, Xavier and Ruggiero, Carmelinda and Ferretti, Roberta and Diestre, Germán and Clarfield, A Mark and Crome, Peter and Hertogh, Cees and Lesauskaite, Vita and Prada, Gabriel-Ioan and Szczerbinska, Katarzyna and Topinkova, Eva and Sinclair-Cohen, Judith and Edbrooke, David and Mills, Gary H}, biburl = {https://www.bibsonomy.org/bibtex/29bfe881316dbbdac0fcb667a10e45c0c/jepcastel}, doi = {10.1001/archinternmed.2011.31}, interhash = {7e504f399386aff09fd3e9d74b33d16f}, intrahash = {9bfe881316dbbdac0fcb667a10e45c0c}, issn = {1538-3679}, journal = {Archives of internal medicine}, keywords = {80andover Aged ClinicalTrialsasTopic Databases Factual HeartFailure HeartFailure:drugtherapy Humans LogisticModels PatientSelection}, month = {3}, note = 6058, number = 6, pages = {550-6}, pmid = {21444844}, timestamp = {2023-02-03T11:44:35.000+0100}, title = {The persistent exclusion of older patients from ongoing clinical trials regarding heart failure.}, url = {http://archinte.ama-assn.org/cgi/content/abstract/171/6/550 http://www.ncbi.nlm.nih.gov/pubmed/21444844}, volume = 171, year = 2011 }